January 2024
1. YOSHIMURA N, Fujiwara M, Igeta M, Suzuki H, et al
   Risk Factors Causing Hypothyroidism in Patients With Head and Neck Cancer After Radiotherapy Using SIB-VMAT.
   Anticancer Res. 2024;44:323-329.
   

   >> Share

   
   November 2023
2. KOWKABANY G, Jimenez PB, Sharan S, Bansal S, et al
   Inequities in Time to Treat Thyroid Cancer.
   Anticancer Res. 2023;43:5025-5030.
   

   >> Share

   
   October 2023
3. ZHOU J, Liu J, Zhang KE, Lv J, et al
   High-throughput Sequencing Analysis of Differentially Expressed microRNAs Associated With SREBP1 in Differentiated Thyroid Carcinoma.
   Anticancer Res. 2023;43:4435-4446.
   

   >> Share

   
   April 2023
4. LANDSTROM F, Sandberg J, Reizenstein J
   Life-threatening Airway Complication After Radioactive Iodine Treatment: A Case Report and Review of the Literature.
   Anticancer Res. 2023;43:1853-1855.
   

   >> Share

   
   March 2023
5. NAKAYAMA H, Saito N, Kasajima R, Suganuma N, et al
   Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines.
   Anticancer Res. 2023;43:1073-1077.
   

   >> Share

   
   January 2023
6. IJAZ K, Yin F
   Papillary Thyroid Carcinoma With Squamous Dedifferentiation: A Potential Diagnostic Pitfall.
   Anticancer Res. 2023;43:255-258.
   

   >> Share

   
   
7. MATSUO M, Baba S, Hashimoto K, Isoda T, et al
   Utility of FDG PET at the Initial Radioiodine Therapy in Differentiated Thyroid Cancer.
   Anticancer Res. 2023;43:183-190.
   

   >> Share

   
   November 2022
8. CHO JS, Kim HK
   Thyroglobulin Levels as a Predictor of Papillary Cancer Recurrence After Thyroid Lobectomy.
   Anticancer Res. 2022;42:5619-5627.
   

   >> Share

   
   September 2022
9. MILAS ZL, Neelands B, Trufan SJ, Benbow J, et al
   Survivorship Care Plans Improve the Identification of Post-radiation Hypothyroidism After Head and Neck Cancer Treatment.
   Anticancer Res. 2022;42:4429-4437.
   

   >> Share

   
   May 2022
10. KUNTE S, Sharett J, Wei W, Nasr C, et al
    Poorly Differentiated Thyroid Carcinoma: Single Institution Series of Outcomes.
    Anticancer Res. 2022;42:2531-2539.
    

    >> Share

    
    
11. ACHILLA C, Papavramidis T, Angelis L, Chatzikyriakidou A, et al
    The Implication of X-Linked Genetic Polymorphisms in Susceptibility and Sexual Dimorphism of Cancer.
    Anticancer Res. 2022;42:2261-2276.
    

    >> Share

    
    
12. KLIMAITE R, Kazokaite M, Kondrotiene A, Dauksiene D, et al
    Diagnostic Value of Circulating Cell-free DNA in Patients With Papillary Thyroid Cancer.
    Anticancer Res. 2022;42:2289-2299.
    

    >> Share

    
    
13. HUANG TS, Lee JJ, Huang SY, Cheng SP, et al
    Regulation of Expression of Sterol Regulatory Element-binding Protein 1 in Thyroid Cancer Cells.
    Anticancer Res. 2022;42:2487-2493.
    

    >> Share

    
    March 2022
14. LIU A, Borges PM, Tay YS, Thompson LDR, et al
    Thyroid Follicular Cell-derived Carcinomas in a Background of Multiple Adenomatous Nodules Leading to a Diagnosis of PTEN Hamartoma Tumor Syndrome in an Adult Patient With a Novel RECQL4 Mutation.
    Anticancer Res. 2022;42:1481-1485.
    

    >> Share

    
    
15. JIN MC, Qian ZJ, Megwalu UC
    Risk of Second Primary Malignancies After External Beam Radiotherapy for Thyroid Cancer.
    Anticancer Res. 2022;42:1359-1365.
    

    >> Share

    
    January 2022
16. MEIROVITZ A, Nisman B, Allweis TM, Carmon E, et al
    Thyroid Hormones and Morphological Features of Primary Breast Cancer.
    Anticancer Res. 2022;42:253-261.
    

    >> Share

    
    November 2021
17. NA YM, Cho JS, Park MH
    Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
    Anticancer Res. 2021;41:5713-5721.
    

    >> Share

    
    July 2021
18. CAO C, Poti SM, Ledgerwood LG, Lai J, et al
    Mixed HPV-related Neuroendocrine Carcinoma and HPV-related Squamous Cell Carcinoma of the Base of Tongue in a Patient With Incidental Identification of Synchronous Metastatic Papillary Thyroid Carcinoma.
    Anticancer Res. 2021;41:3639-3642.
    

    >> Share

    
    March 2021
19. FUKUDA N, Toda K, Ohmoto A, Wang X, et al
    Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib.
    Anticancer Res. 2021;41:1683-1691.
    

    >> Share

    
    
20. MARCHAND-CRETY C, Pascard M, Debreuve-Theresette A, Ettalhaoui L, et al
    Prognostic Factors and Survival Score for Patients With Anaplastic Thyroid Carcinoma: A Retrospective Study from a Regional Registry.
    Anticancer Res. 2021;41:1555-1561.
    

    >> Share

    
    December 2020
21. LORNTZSEN B, Jacobsen AB, GrOholt KK, Sigstad E, et al
    Survival and Surgical Complications in Anaplastic Thyroid Cancer Patients After Completed Multimodal Treatment.
    Anticancer Res. 2020;40:6979-6985.
    

    >> Share

    
    November 2020
22. KIM SH, Cho YK, Huh JH, Kang JG, et al
    Heat Shock Protein 90 Inhibitors AUY922, BIIB021 and SNX5422 Induce Bim-mediated Death of Thyroid Carcinoma Cells.
    Anticancer Res. 2020;40:6137-6150.
    

    >> Share

    
    
23. NISMAN B, Allweis TM, Carmon E, Kadouri L, et al
    Thyroid Hormones, Silencing Mediator for Retinoid and Thyroid Receptors and Prognosis in Primary Breast Cancer.
    Anticancer Res. 2020;40:6417-6428.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share